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Abstract
Hepatitis C virus infection leads to liver disease whose severity can range from mild to serious lifelong illness.
However the parameters involved in the evolution of the disease are still unknown. Among other factors, the
virus-elicited antibody profile is suspected to play a role in the outcome of the disease. Analysis of the relationship
between anti-virus antibodies and disease state requires the analysis of a large number of serums from patients
(hepatitis C virus+) and of epitopes from the viral proteins. Such a study would benefit from microarray-based
screening systems that are appropriate for high-throughput assays.
We used a method combining peptide chips and surface plasmon resonance imaging previously shown to be
suitable for analyzing complex mediums and detecting peptide-protein interactions. 56 peptides covering the entire
viral proteome were grafted on chips and their interaction with antibodies present in the 68 injected serums from
infected and non-infected donors was measured. Statistical analyses were conducted to determine a possible
relationship between antibodies (specificity and amount) and disease states.
A good discrimination between infected and non-infected donors validated our approach, and several correlations
between antibodies profiles and clinical parameters have been identified. In particular, we demonstrated that ratios
between particular antibodies levels allow for accurate discrimination of patients according to their pathologic
states.
Conclusion: Humoral response against hepatitis C virus linear epitopes is partly modified according to the disease
state. This study highlights the importance of considering relative quantities of antibodies with different specificities
rather than the amount of each antibody.
Keywords: Antibody; Epitope; Hepatitis C virus; Peptide chip; SPR imaging
Introduction
Although hepatitis C virus (HCV) induces a strong
humoral response within a few weeks after infection,
only 25-30% of the infected individuals resolve the
disease whereas the rest develop chronic hepatitis C.
Among the latter group, 20% progress to cirrhosis,
whereof 5% further evolve towards hepatocellularcarci-
noma (HCC) (Zein 2003). The parameters determining
the outcome of the infection remain unknown. Indeed,
cellular and humoral immune responses work together
to protect individual against infections, but are also
suspected to induce liver damage associated with HCV
infection (reviews (Gremion and Cerny 2005; Irshad
et al. 2008)). As antibodies (Ab) play a key role in im-
mune response, they are believed to be involved in the
outcome of HCV disease. It is well known that HCV
elicits antibodies against both structural and non-
structural proteins (Gabrielli et al. 1996; Gutierrez et al.
2011; Sillanpaa et al. 2009) and several studies have
investigated a possible relationship between immuno-
reactivity and clinical features. While a correlation
between viremia and Ab titres has been established
(Bassett et al. 1998; Lohr et al. 1996; Yuki et al. 1994),
studies attempting to discriminate between acute and
chronic phases or between responders and non-responders
to treatment led to more controversial results (Araujo et al.
2011; Hilfenhaus et al. 1992; Lohr et al. 1996). However,
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most of these studies have focused on the occurrence of
Ab directed against different viral proteins without regards
to their quantification. Moreover, they are often limited by
the use of recombinant large proteins or polypeptides as
probes to analyse anti-HCV Ab, which allows for a global,
rather than precise determination of their specificity. A
more accurate analysis using smaller peptides as probes
could increase the number of identified epitopes targeted
by anti-HCV Ab while also indicating their specificity. Al-
though allowing for the detection of linear epitopes only,
this approach can be useful in the case of HCV infection
since human Ab are mainly directed against linear epitopes
of the virus (Sallberg et al. 1992). It also benefits from the
recent development of microarray-based screening sys-
tems. This technology has found its first applications in
gene expression screening, and DNA/RNA microarrays
have been used in clinical research for predicting the out-
come of the disease (van’t Veer et al. 2003; Zhao et al.
2006), response to treatment (Augustine et al. 2009) or for
determining cancer class (Golub et al. 1999). More difficult
to implement, protein microarrays have emerged later and
still remain rarely used: the complexity and heterogeneity
of the probes together with the necessity to preserve their
conformational folding impair their benefit. Peptide micro-
arrays are therefore a good alternative to protein arrays
and are suitable for large screening. They have demon-
strated their reliability in detecting specific Ab content in
serums, allowing one to test both a wide range of potential
epitopes and a large number of samples (Cherif et al. 2006;
Maksimov et al. 2012; Perez-Gordo et al. 2012; Villiers
et al. 2010; Villiers et al. 2011).
Using such a technology with a set of probes comprising
56 peptides spanning the entire HCV proteome, our aim
was to analyse the HCV-elicited immune response in 45
HCV-positive donors. Both the occurrence and magnitude
of each Ab response were determined using surface plas-
mon resonance imaging (SPRi) to detect Ab-peptide in-
teractions. We investigated a possible relationship between
immuno-reactivity and various clinical parameters such as
state of the disease (chronic, cirrhotic, HCC), viremia,
ALAT (alanine amino-transferase) level, and Metavir
scores. A good discrimination between HCV-positive
and negative donors validated our approach, and several
correlations between Ab profiles and clinical parameters
have been identified. In particular, we demonstrated
that ratios between particular Ab levels allow for accur-
ate separation of the three states of the disease.
Materials and methods
Serums
Human serums were provided by the Etablissement
Français du Sang (Grenoble, France) and the Centre
Hospitalo-Universitaire, Grenoble, France. The cohort in-
cluded 15 serums from healthy donors, 8 serums from
HCV-negative patients (HCV-) with alcoholic cirrhosis
(HCC-OH) and 45 serums from HCV-positive patients
(HCV+) infected with genotype 1b, at various stages of
the disease: chronic hepatitis C (15 serums), cirrhosis (16
serums) and hepatocellularcarcinoma (HCC) (14 serums).
Clinical data are shown in Additional file 1. All partici-
pants provided written informed consent. Rabbit immune
serum against HCV peptide C131 (control serum) was
prepared by NeoMPS (Strasbourg, France).
Peptides
Peptides were synthesized by Altergen (Bischheim, France)
with a pyrrole-modified –NH2 (Villiers et al. 2009). Fifty-six
peptides are derived from HCV genotype 1b (ExPASy
accession number P26663), one from hen egg lysozyme
(P00698, control peptide).
SPR analysis
Glass prisms coated with a 50 nm gold layer were obtained
from HORIBA-Scientific (Palaiseau, France). Peptides
(100 μM) were grafted in duplicate on the biochip sur-
face by electrochemical copolymerization (Villiers et al.
2011), using an Omnigrid Micro-robotic arrayer (Horiba-
Scientific). Ab binding on the grafted peptides was detected
using Surface Plasmon Resonance imaging (SPRi). This
optical technique allows for the detection of protein-
peptide interaction through a change in the intensity of
the reflected light. Successive serum injections (1:50 in
PBS) were performed as previously described (Villiers
et al. 2011). Stabilization of the peptide chip was en-
sured by twelve blank injection/regeneration cycles
before sample analysis. Periodic injections of control
rabbit anti-C131 serum (1:200) allowed to monitor the
reduction of signal along successive injections and to
model it using polynomial curve. This curve was used
to determine a correction factor to be applied to sample
injections (Villiers et al. 2011). SPR signals were mo-
nitored at 810 nm using a surface plasmon resonance
imager SPRi-Plex from Horiba-Scientific. Measurements
were performed using SPRi-dedicated software (Horiba-
Scientific).
Statistical analysis
Ratio calculations and Mann–Whitney tests were per-
formed using R v2.15.1. Hierarchical clustering (Pearson’s
correlation, average linkage) and heatmaps were generated
using Genesis software (release 1.7.6, Graz University of
Technology, Austria) (Sturn et al. 2002).
Multivariate data analysis was conducted using Soft
Independent Modeling of Class Analogy (SIMCA) with
Partial Least Square (PLS) regression and Discriminant
Analysis (DA): PLS-DA is a regression analysis that takes
advantage of class information to attempt to maximise
the separation between groups of observations (SIMCA-P,
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Umetrics AB). R2 is an estimate of the proportion of vari-
ance explained by the model and Q2 an estimate of the
predictive ability of the model.
Results
Selection of the grafted peptides
To analyse the specificity of anti-HCV Ab in serums,
peptides to be used as probes were selected according
to various criteria. Sequences were derived from geno-
type 1b, the most common in Europe (Chen and Weck
2002). The length of the peptides was about 20 resi-
dues to ensure good accessibility. Furthermore, assum-
ing that potential antigenic regions are predominantly
located at the surface of the proteins (Chen et al. 2007;
Novotny et al. 1986), hydrophilic peptides were favoured.
The high rate of mutation occurring in HCV affects
epitope recognition by the Ab. Thus, peptide sequences
were chosen in regions exhibiting relatively conserved se-
quences across genotypes. In order to have an overview of
the humoral response against conserved linear epitopes,
the selected peptides (Additional file 2) were derived from
all HCV proteins.
Overall analysis of antibody-targeted epitopes
We first analysed the linear epitopes recognized by the
Ab present in HCV + serums. As previously described,
the SPR signal in the range of 0.5% to 10% detected
from each grafted peptide is proportional to the con-
centration of its corresponding specific Ab present in
the sample (Cherif et al. 2006). Two parameters were
analysed for each peptide: the percentage of patients
exhibiting SPR signal > 0.5 (i.e. medium/large response
(Figure 1a) and the mean value of this signal (Figure 1b).
Anti-HCV response is mainly directed against the Core
Figure 1 Targeted epitopes. 45 HCV + serums were injected on the chip, and the SPR signals obtained from the different grafted peptides were
measured. Data represent mean of three independent experiments. (a) Percentage of patients with significant SPR signal (≥ 0.5) for each peptide.
(b) Mean value of SPR signals (change in reflectivity = ΔR) obtained on each peptide for all patients. (c) Correlation between Ab amount against a
peptide and the percentage of patients with Ab recognizing this peptide
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protein, particularly against the first N-terminal aa residues
(1–80): more than 80% of the patients possess Ab directed
against the first 40 aa. NS4 and NS5A are also well rec-
ognized by Ab, though to a lesser extent. The tested
peptides from both envelope (E1 and E2) and non-
structural NS2, NS3 and NS5B proteins are poorly im-
munogenic as the signals obtained for these sequences
are low and rare. In most cases, the C-terminal portion
of the proteins does not elicit a strong Ab response:
less than 5% of the patients possess a medium/large
amount of Ab against peptides from Core 150–189, E1
271–380, E2 605–702, and NS2 1002–1023. Overall, a
good correlation (R2 0.914) is found between Ab fre-
quency and amount (Figure 1c). For the following ana-
lyses and to minimize the individual variations in the
ability to synthesize Ab, we used normalized data. For
each serum, SPR signals were expressed as a percentage
of the response obtained for all the peptides tested.
Analysis of the correlation between the epitopes targeted
by Ab
First, we evaluated the correlation between the different
SPR signals (i.e. Ab amount in each HCV + serum) ob-
tained for each peptide. Hierarchical clustering analysis
using the Pearson’s correlation led to the identification
of four groups of peptides (Figure 2):
– The first group (blue) includes the first N-Ter pep-
tides from Core (C1-C7).
– The second group (red) includes the remaining
peptides from Core (C8-C18), the peptides from
E1 and NS3.
– The third group (green) consists of peptides from E2
(except E2-3) and some of those from NS4 and NS5,
including the C-Ter NS5-4 and NS5-7.
– The fourth group (pink) is constituted by the
remaining peptides from NS4 and NS5 proteins.
Figure 2 Correlation between epitopes recognized by the Ab present in tested serums. Heatmap generated from Pearson’s correlation
analysis. Identification of four peptide groups (1–4). Data represent mean of three independent experiments.
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These results are confirmed by principal component ana-
lysis (data not shown). In this case, NS5-8 is included in
group 3, whereas C15 and E2-3 does not fit in any group.
Correlation between Ab specificity/amount and disease
state
To establish a correlation between the Ab profile of the
tested serums and the clinical diagnosis of the corre-
sponding donors, the patients were clustered based on
the signal intensity that their serum triggered for all of
the 56 peptides. While hierarchical clustering (Pearson’s
correlation) successfully discriminates between HCV + and
HCV- patients (Figure 3), no clear separation of the differ-
ent disease states can be established by this approach.
Thus, we used Partial Least Square Discriminant Ana-
lysis to find a model that separates classes of observa-
tions (here 5 classes) based on their descriptive variables
(peptides). This approach allows us to identify 3 clusters
as shown in Figure 4. As expected, a very good se-
paration between HCV- (HCC-OH and healthy) and
Figure 3 Peptide probe/serum pairwise SPRI intensity values. SPRI signal intensities from each peptide probe (columns) were collected after
sequential exposure of the chip to various serums (rows) and are displayed as a heatmap. Dendrograms show the hierarchical clustering of the
considered variables using the Pearson correlation coefficient, average linkage clustering method. Data correspond to the mean of three
independent experiments.
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HCV + serums is observed, with high degree of fit
(R2 0.815) and predictability (Q2 0.692). In addition,
HCC patients can be grouped into one cluster, leaving
chronic and cirrhosis patients together in a third clus-
ter (R2 0.463, Q2 0.215).
Then, we investigated whether it was possible to estab-
lish a model for accurate discrimination between all the
various states of HCV disease. The entire dataset is di-
vided into a training set (to build a model), and a test
set (to validate the model).
Table 1 summarizes 10 different clustering models that
were evaluated using this approach. By breaking down the
dataset to only two disease states (HCV + and HCV-;
Model #1), we were able to obtain more than 95% correct
classification, confirming the previously evidenced clus-
ters. ALAT-based (threshold = 2 N; Model #9) and viral
load-based (threshold = 600,000 UI; Model #10) clustering
were also found to be particularly relevant with a mini-
mum correct classification of 90.9% and 100%, respect-
ively. However regardless of the clustering of the training
dataset with respect to the pathology (Models #2 to 5), or
with respect to the Metavir scores (Models #6, 7 and 8),
no models yielded an accurate classification of the test set.
Separation of each disease state from the others
Since the global Ab profile of each patient, as analyzed by
PLS-DA, does not allow for valid predictive model of the
disease state, we investigated the possibility of using par-
ticular Ab as specific markers of the various diagnoses.
For each of the peptides, we performed a Mann–Whitney
test between the 3 disease groups to evaluate the (dis)simi-
larity of the Ab signal they mediated and to identify Ab
which amount can be correlated to a specific state of the
disease (healthy patients were not included). Four peptides
exhibit significant differences in the signal they triggered
between at least 2 patient groups (p < 0.05), whereof only
one (NS3-3) can efficiently separate one disease state
from the 2 others (Figure 5). Three peptides are signifi-
cantly more recognized by Ab present in serums from
cirrhotic patients than from chronic (C15 and NS3-6) or
HCC patients (NS4-1), and Ab recognizing NS3-3 are sig-
nificantly lower in the case of chronicity compared to both
cirrhosis (p 0.048) and HCC (p 0.047).
Correlation between Ab specificity/amount and various
clinical parameters
Humoral response upon HCV infection was analysed
using PLS-DA in correlation with various parameters used
by clinicians to assess the severity of the disease: Metavir
scores, ALAT activity, and viral load. When considering
the total amount of all anti-HCV antibodies, regardless of
their specificity, no correlation is observed with either
ALAT level or viral load (data not shown). However, when
we consider each Ab individually, good correlations are
observed with ALAT level (threshold 2 N) and with viral
load (threshold 600 000 UI), allowing for predictive models
leading to more than 90%, and even to 100% correct classi-
fication for ALATand viral load, respectively (Table 1).
Figure 4 Correlation between Ab specificity and disease state using partial least square discriminant analysis. The graph provides
the plan which separates the 5 given classes as well as possible, according to the descriptive variables. Data represent mean of three
independent experiments.
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Analysis of SPR signal ratios
To enhance the sensitivity of the study, we decided to
analyse the ratio of SPR signals from pairs of peptides
rather than from individual peptides. This strategy iden-
tifies, among all possible combinations, several Ab ratios
for which there is a significant difference (p < 0.05) be-
tween one state of the disease and the two others
(Table 2 and Additional file 3). Two ratios allow for the
separation of cirrhotic patients from chronic and HCC
ones, whereas 15 and 14 ratios distinguish chronic and
HCC, respectively, from the two other states. Remark-
ably, one ratio (C11/NS3-3) is shown to separate each
state from the others.
Discussion
The aim of this study was to analyse the specific humoral
response developed upon HCV infection, taking advantage
of the potentialities of microarray-based screening sys-
tems. Previous studies dealing with anti-HCV Ab were
informative but restricted to a global determination of
their specificity because of the size of the probes that did
not allow for precise identification of the epitopes. More-
over, the clinical parameters associated with the pathology
that were taken into account were often restricted to the
viral load, the response to the treatment or to two states
of the disease, usually acute and chronic (Araujo et al.
2011; Desombere et al. 2007; Sillanpaa et al. 2009). The
use of peptide microarrays together with SPRi detection
allows for more accurate identification of epitopes to-
gether with Ab quantification and is suitable for a large
screening of both probes and serums (Cherif et al. 2006).
Three main reasons guided us to use 20aa peptides as
probes to determine the specificity of anti-HCV Ab. First,
peptide microarrays are more stable than protein arrays
Table 1 Classification of Ab specificity versus disease state
Parameter Model # Disease state Number of serums Correct classification (%)
HCV 1
+ 45 100
- 23 95.7
Pathology
2
Chronic hepatitis 15 93.3
Cirrhosis 16 75
HCC 14 100
HCC-OH 8 37.5
Healthy 15 80
3
Chronic hepatitis 15 60
Cirrhosis 16 56.2
HCC 14 0
Healthy + HCC-OH 23 100
4
Chronic hepatitis + Cirrhosis 31 87.1
HCC 14 0
Healthy + HCC-OH 23 100
5
Chronic hepatitis 15 0
Cirrhosis + HCC 30 90
Healthy + HCC-OH 23 95.6
Metavir F (score) 6
0+1 13 92.3
2 14 0
3+4 27 86.4
Metavir A (score)
7
1 14 100
2 17 82.3
3 7 0
8
1+2 31 78.6
3 7 91.7
ALAT/Norm ALAT 9
≤ 2N 23 90.9
> 2N 18 97.7
Viral load (UI) 10
< 600 000 8 100
> 600 000 30 100
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and are thus more suitable for large screening (Villiers
et al. 2011). Second, it is established that human Ab elic-
ited by HCV infection are mainly directed against linear
epitopes (Sallberg et al. 1992). Third, it is usually consid-
ered that linear B cell epitopes typically vary from 6 to
20aa in length with a mean value of 13aa (Sollner 2006).
The great immunogenicity of the Core protein (Figure 1),
as revealed by using these peptides as probes, is in agree-
ment with previous works using larger sequences (Araujo
et al. 2011; Chen et al. 1999). This suggests that a large
proportion of the Core epitopes are actually linear. This
does not seem to be the case for the other viral proteins,
especially envelope and NS2-NS3 proteins, since poor
antibody responses against linear epitopes from these pro-
teins are found in our study (Figure 1). Although we can-
not exclude that this observation may partly result from
the fact that the selected peptides do not cover the entire
sequence of the protein (as opposed to Core-derived pep-
tides), the low amount of Ab directed against these regions
was also observed in other analyses using peptides as
probes (Sallberg et al. 1993). In contrast, authors using
polypeptides or recombinant proteins detected anti-E1,
anti-E2 (Chen et al. 1999; Zibert et al. 1999), and anti-NS3
(Hwang et al. 1996; Yuki et al. 1994) in more than 50% of
the tested serums. Moreover, it is known that E1-E2 pro-
vide several conformational epitopes for neutralizing Ab
(Giang et al. 2012; Law et al. 2008). In addition, and des-
pite the fact that peptide sequences were chosen in regions
exhibiting relatively conserved sequences across geno-
types, the presence of three hypervariable regions in E2
makes it difficult to identify common epitopes. In the Core
protein, the immunodominant region lies within the first
90aa, which are probably more exposed than the others as
suggested by the hydrophobicity index (Gravy) of the se-
quence (−1.442 (aa 1–89) versus 0.313 (aa 90–189)). This
is due to the presence of two regions with a high density
of basic residues (leading to hydrophilic regions) in the
N-ter portion of the protein (Klein et al. 2005).
We first examined whether there was any correlation
between the peptides recognized by serum Ab. Statistical
studies by either PLS-DA or hierarchical clustering using
Pearson’s correlation determine four groups of peptides
(Figure 2). As expected, peptides that possess a 10-aa
overlapping sequence tend to stand in the same group.
However, the Core protein presents two independent
regions with regards to its antigenicity, as previously ob-
served (Nasoff et al. 1991), which distinguish the first 80
aa (N-ter) from the rest of the molecule. This suggests a
difference in the structure and/or the behaviour of the
N-ter compared to the C-ter regions of the Core protein,
which is supported by the difference in the hydropho-
bicity index between them. Analysis of aa sequences of
different HCV genotypes shows three domains in the
Core protein, one of them (N-terminal region) spanning
residues 1–118 that roughly corresponds to the most im-
munogenic portion of the protein (Hope and McLauchlan
2000). The observed correlation between the amounts of
Ab against E1 and the C-ter part of the Core can be re-
lated to the correlation between circulating core and E1
levels (El Awady et al. 2006).
Then we looked for a relationship between Ab specifi-
city or amount and disease state. The very good separation
between HCV- and HCV+ patients obtained using hier-
archical clustering (Figure 3) and PLS-DA (95% correct
classification, Table 1) validates the methodology used in
our study, especially the normalization of the signals.
However, this approach is not sufficient for discrimination
between each state of the disease, which would provide a
good prognosis tool. Despite different Ab profiles in the
serums from HCC versus chronic + cirrhotic patients, Ab
Figure 5 Peptides differently targeted by Ab with respect to the disease state. 45 HCV + serums from patients at various stages of the
disease were injected on the chip, and SPR signals obtained from the different grafted peptides were measured (change in reflectivity = ΔR).
Asterisks denote significantly different signals (pval≤ 0.05) between groups as evaluated by Mann–Whitney test.
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profiles fail in affording correct classification of all patient
samples, even after merging different disease states.
However, the lack of a predictive model does not mean
a lack of significant differences between Ab profiles with
regard to the disease states. The Mann and Whitney test
reveals that only 4 peptides out of the 56 tested are
recognized to different extents by Ab from at least two
categories of serums (Figure 5): serums from cirrhotic
patients display a significant difference in Ab amount
against C15 and NS3-6 compared to chronic patients
and against NS4-1 compared to HCC patients. However
only one peptide, NS3-3, is recognized differently by the
Ab from the three disease states. Three of these peptides
belong to group 2, whereas none of them belong to
groups 1 and 4. It is noticeable that all these 4 peptides
lead to a low average SPR signal, resulting in a low (C15
and NS4-1) or null (NS3-3 and NS3-6) percent positive
patients when focusing on easily detectable antibodies
(SPR signal threshold > 0.5, Figure 1). It is possible that
the high immunogenicity of the peptides of group 1
dwarfs differences between disease states. On the other
hand, too weak immunogenicity, as for peptides from
the envelope, can lead to the same result. Overall, our
data demonstrate a very weak specificity of the Ab re-
sponse with regard to the disease state, which is unlikely
to be due to the linear nature of the epitopes tested. In-
deed, a study using chimpanzees and large polypeptides
derived from Core and NS3/NS4 concludes that Ab
Table 2 Ab ratios allowing for a separation of each disease state from the two others (Mann–Whitney analysis)
Ab
ratio1
Chronic hepatitis Cirrhosis HCC
Versus cirrhosis Versus HCC Versus chronicity Versus HCC Versus chronicity Versus cirrhosis
Epitope C5/C18 C11/NS3-3 C10/NS3-3
p.value 0.030 0.011 0.045 0.043 0.018 0.047
Epitope C5/E1-8 E2-3/NS4-1 C11/NS3-3
p.value 0.041 0.017 0.017 0.013 0.007 0.043
Epitope C5/NS3-3 C13/NS4-1
p.value 0.030 0.009 0.026 0.000
Epitope C5/NS3-6 C15/NS4-1
p.value 0.009 0.013 0.029 0.047
Epitope C6/C18 E1-3/NS4-1
p.value 0.030 0.033 0.009 0.001
Epitope C6/NS3-3 E2-4/NS4-1
p.value 0.041 0.037 0.016 0.007
Epitope C7/C18 E2-5/NS4-1
p.value 0.019 0.046 0.029 0.002
Epitope C11/C18 E2-11/NS4-1
p.value 0.021 0.033 0.016 0.015
Epitope C11/E1-8 E2-12/NS4-1
p.value 0.021 0.041 0.003 0.022
Epitope C11/NS3-3 NS2-2/NS4-1
p.value 0.045 0.007 0.033 0.031
Epitope E1-4/NS3-3 NS3-3/NS4-1
p.value 0.019 0.041 0.020 0.007
Epitope E2-12/NS4-7 NS4-1/NS4-3
p.value 0.037 0.020 0.012 0.010
Epitope NS4-2/NS4-7 NS4-1/NS5-4
p.value 0.049 0.033 0.008 0.022
Epitope NS4-3/NS5-1 NS4-1/NS5-7
p.value 0.027 0.041 0.041 0.034
Epitope NS4-7/NS5-4
p.value 0.045 0.009
1SPR ratio values are given in Additional file 3.
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patterns are similar in persistently infected animals and
those that cleared viraemia (Hilfenhaus et al. 1992); also,
acute and chronic infections are not discriminated in
a study based on the measurement of Ab reactivity of
human serums against polypeptides from Core and non-
structural proteins (Araujo et al. 2011).
We wondered whether other clinical parameters could
account for the establishment of particular Ab profiles.
Correlations with several parameters are highlighted by
our study (Table 1). First, Ab patterns are related to
Metavir A when scores 1 + 2 are merged, providing a
predictive model allowing for more than 75% correct
classification. The interdependence between Ab profiles
and some clinical parameters is even stronger when
considering ALAT values (correct classification > 90% -
threshold = 2 N) and viral load (correct classification
100% - threshold = 600 000 UI). Few studies deal with
the correlation between ALAT and anti-HCV Ab; Lohr
et al. (Lohr et al. 1996) observed that patients whose
lymphocytes secreted anti-HCV in vitro had higher ALAT
levels in serum, and Brillanti et al. (Brillanti et al. 1992)
observed a positive correlation between the ALAT and
anti-HCV IgM levels. However, our result, in agreement
with Nikolaeva et al. (Nikolaeva et al. 2002), do not reveal
any correlation between ALAT levels and anti-HCV titres.
Further studies aimed at correlating anti-HCV Ab and
viral load however they usually show a correlation be-
tween total anti-HCV Ab titres and viremic levels. This
discrepancy between these studies and ours may be due to
the probes used for anti-HCV quantification consisting of
large recombinant proteins (Bassett et al. 1998; Gane et al.
1999; Yuki et al. 1996) rather than peptides.
Thus, we demonstrate that although HCV infection
elicits different Ab profiles in patients, only a very few
linear epitopes are significantly different in the response
they trigger by serums from chronic, cirrhotic, and HCC
states. All these results led us to hypothesize that the
different stages of the disease may be less correlated
with the absolute value of the immune response against
each viral protein than with the relative value of Ab rec-
ognition of different epitopes. This prompted us to ana-
lyse the ratio of SPR signals grouped in pairs of peptides
(Table 2). This original approach improves the sensitivity
of the analysis by reducing the impact of differences in
the amplitude of humoral immune responses observed
between patients. First, it reveals that Ab ratio for one
peptide pair (C11/NS3-3) is an accurate marker of each
state of the disease. Anti-NS3-3 alone was already iden-
tified in this study to separate the chronic state from a
group consisting of cirrhotic and HCC states (Figure 5).
Furthermore, association with anti-C11 allows for distin-
guishing cirrhotic from HCC states (Table 2). Second, a
large number of peptide pairs discriminate chronic and
HCC (15 and 14 pairs, respectively) from the two other
states. Interestingly, we observed that the majority of the
peptide pairs allowing for separation of the chronic state
are intergroup (66.7%) In contrast, only 28.6% of the ra-
tios used to discriminate between HCC and other states
involve peptides belonging to different groups. In the
first case, peptides from the Core protein are often im-
plicated (66.6%) while NS4-1 is the most represented
peptide in the second case (85.7%). Cirrhosis is the most
difficult state to identify. This is not surprising since it is
an intermediate state between chronicity and HCC.
Although direct profiling of Ab specificity does not pro-
vide an accurate prognostic tool, our study demonstrates
that humoral response against HCV linear epitopes is
modified according to disease state. This relationship does
not result in a significant change in the overall immune
response against individual epitopes. However, relative
amplitudes of Ab responses against selected pairs of
epitopes appear to be relevant in discriminating disease
states. Overall, SPRi system for high-throughput screening
has allowed for a thorough analysis of Ab specificity
against multiple epitopes directly from patients serums.
Our data reveal a set of peptides derived from HCV
related to the state of the disease. This method opens po-
tential further studies aiming to decipher the host- and
pathogen-dependent molecular processes underlying the
infections and the evolution of the resulting diseases.
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